REGISTER
ASCO 2026 in Gynecologic Oncology: Four Shifts Reshaping the Treatment Landscape
At ASCO 2026, gynecologic oncology moved past headline-making phase III readouts toward questions about sequencing, combination, and patient selection. ADCs emerged as a multi-target treatment platform; long-term follow-up of NRG-GY018 and RUBY reframed the immunotherapy conversation around cure fractions; and two negative studies (CHRONO, MIROVA) showed that absence of benefit can still sharpen practice. The field is shifting from access to novel agents toward mastering their use.

A Different Kind of ASCO for Gynecologic Cancers

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting convened more than 40,000 oncology professionals in Chicago and featured several thousand abstracts spanning basic, translational, and clinical research. The gynecologic oncology program did not deliver a single practice-changing phase III readout on the scale of LACC or KEYNOTE-A18, but the aggregate of mature follow-up data, new drug studies, and carefully designed negative trials may, in aggregate, prove more instructive than a single landmark result.

As noted in a recent synthesis published in the International Journal of Gynecologic Cancer (IJGC), the data presented at ASCO 2026 point to a field that is no longer asking whether new modalities work, but how to deploy them. Four themes stood out: the maturation of antibody-drug conjugates (ADCs) into a multi-target platform; the reframing of immunotherapy around cure rather than progression-free survival (PFS); the clinical value of well-conducted negative trials; and the displacement of drug access by drug stewardship as the field’s central problem.

1. ADCs Are Becoming a Treatment Platform, Not a Single Drug

A decade after the first clinically meaningful ADCs reached ovarian and cervical cancer, ASCO 2026 reflected a portfolio rather than a product. The gynecologic oncology program included early- and mid-stage data on ADCs directed against at least six antigens, spanning ovarian, endometrial, and cervical cancer.

Tumor Type

ADC Targets with Reported Studies at ASCO 2026

Ovarian cancer

FRα (mirvetuximab and follow-on agents); NaPi2b (e.g., TUB-040); c-Met (e.g., ABBV-400 / telisotuzumab adizutecan); B7-H4 (e.g., AZD8205)

Endometrial cancer

FRα ADC combined with PD-1 inhibitors

Cervical cancer

Nectin-4 ADC; TROP-2 ADC

Table. 1. ADC Targets Investigated Across Gynecologic Malignancy Trials Presented at the 2026 ASCO Annual Meeting

The clinical conversation, conference participants noted, has moved through three phases. Early experience centered on the question of whether an ADC was available at all; the current question is which ADC to select; and the questions now being posed at tumor boards and in trial design are when in the treatment course to use an ADC, how to sequence one ADC after another, and whether meaningful activity persists after a patient has already received a different ADC.

The translational implication is that ADC development in gynecologic malignancies is increasingly an exercise in target selection and combination strategy rather than payload optimization. Preclinical data presented at the meeting suggested differential activity of FRα, NaPi2b, and B7-H4 ADCs according to antigen density and tumor histology, but these observations have not yet been correlated with head-to-head clinical outcomes. Whether ADC-after-ADC sequences produce meaningful benefit remains an open question and one that ongoing trials such as those evaluating mirvetuximab in earlier lines are positioned to address.

2. Immunotherapy Is Being Reframed Around Cure

Two mature long-term follow-up analyses dominated the immunotherapy conversation in gynecologic cancers: updated overall survival (OS) from NRG-GY018 and the first modeled estimate of a “cure fraction” from RUBY.

NRG-GY018: Timing Matters

NRG-GY018 evaluated pembrolizumab added to standard chemotherapy in the front-line treatment of advanced or recurrent endometrial cancer. The updated analysis, presented in Chicago, suggests a sustained OS benefit for the pembrolizumab arm even though a large proportion of patients in the control arm subsequently received an immune checkpoint inhibitor. According to the investigators, the data support the interpretation that earlier use of PD-1 blockade may produce a qualitatively different outcome than later use, although the underlying biological explanation for that difference is not yet fully established.

RUBY: A Statistical, Not Yet a Clinical, Cure Fraction

The RUBY trial previously established that dostarlimab plus carboplatin and paclitaxel improves PFS in advanced or recurrent endometrial cancer, with the largest effect in the dMMR/MSI-H subgroup. At ASCO 2026, the investigators presented a statistical model estimating that approximately 54% of patients with dMMR/MSI-H tumors treated in this way may enter a state of long-term disease control consistent with a cure fraction. The figure is a model-based estimate, not an observed cure rate, and the authors were careful to frame it as a hypothesis for further validation.

Important caveat

A modeled cure fraction is not equivalent to a documented cure. It describes a probability that a patient will not experience a disease-related event over a defined time horizon, conditional on having remained event-free to that point. The clinical community has only begun to discuss immunotherapy in these terms, and the 54% figure should be read as a research signal, not as a treatment guarantee.

The historical arc is informative. A decade ago, the question was whether checkpoint inhibitors would produce any activity in gynecologic cancers; five years ago, it was whether they would extend survival; today, the question is whether a meaningful share of patients can be durably controlled, or even considered functionally cured. NRG-GY018 and RUBY do not, by themselves, answer that question, but they have made it the central question for the next generation of trials.

3. Negative Studies Are Starting to Carry Their Weight

Two of the most clinically actionable datasets at ASCO 2026 did not meet their primary endpoints. Both were considered by discussants to be among the most useful results of the meeting.

CHRONO: Cycles of Neoadjuvant Chemotherapy

CHRONO asked a deceptively simple question: in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer, is the standard three-cycle regimen truly necessary, or could six cycles be superior? The trial, which randomized patients between interval debulking surgery after three cycles and continuing to six cycles before surgery, did not meet its primary endpoint for superiority. According to the investigators, the implication is that, for patients with continued chemosensitive disease, deferring surgery for medical, surgical, or resource-related reasons may not, in itself, worsen prognosis. The result gives treating teams additional flexibility without requiring them to compromise on outcome.

MIROVA: Moving an ADC Earlier in the Treatment Course

MIROVA tested whether mirvetuximab, an FRα-directed ADC already approved in FRα-high platinum-resistant ovarian cancer, could improve PFS when moved earlier, into the platinum-sensitive recurrent setting, against standard chemotherapy. PFS did not exceed that of standard chemotherapy in the overall study population. The negative result is best read as a first attempt to challenge chemotherapy’s position earlier in the disease course. ADCs are no longer positioned solely as late-line options of last resort, but the precise patient population and line of therapy in which they will outperform chemotherapy remain to be defined.

Together, CHRONO and MIROVA illustrate a maturing design culture in gynecologic oncology. Trials that test reasonable hypotheses and report them clearly, regardless of the result, are increasingly valued for the same reason that positive studies are: they reduce the number of decisions clinicians have to make on the basis of indirect evidence.

4. The Next Question Is How to Use What We Already Have

For most of the past two decades, the dominant constraint in gynecologic oncology has been the limited number of effective systemic agents. That constraint is, if not gone, then materially weaker: ADCs are accumulating, checkpoint inhibitors are better characterized, PARP inhibitors (PARPi) are being optimized, and additional targeted agents are in development. The problem that ASCO 2026 made newly visible is one of decision-making rather than access.

Practical questions left open by the data presented in Chicago include:

· For patients with FRα-high tumors, when in the treatment sequence should mirvetuximab be deployed?

· Will NaPi2b-directed ADCs move into earlier lines, and on the basis of which biomarker?

· How should TROP-2-, Nectin-4-, B7-H4-, and c-Met-directed ADCs be ordered against one another, and against chemotherapy?

· Are ADC + PD-1 inhibitor combinations superior to ADC followed by PD-1 inhibitor (or vice versa)?

· Is there clinically meaningful activity when a patient receives a second ADC after progressing on a first?

· Which patients should be treated with combinations, and which with sequential monotherapy?

· How should molecular subtypes be used to stratify patients to first-line therapy?

None of these questions, conference participants emphasized, can be resolved by a hazard ratio alone. Decisions are becoming dependent on biomarker-defined subgroups, prior therapy, and treatment tolerability in ways that no single trial can capture. The implication is that the next generation of clinical research in gynecologic oncology will be at least as much about study design, biomarker development, and real-world evidence integration as it is about new molecules.

Limitations and Next Steps

Several caveats apply to the ASCO 2026 dataset in gynecologic oncology as a whole. Many of the ADC reports are early-phase or single-arm, and cross-trial comparisons of agents directed against different antigens should be interpreted with caution. Long-term follow-up of NRG-GY018 and RUBY is informative but does not, by itself, establish cure; cure-fraction modeling is sensitive to assumptions about the shape of the survival curve and the duration of follow-up. The negative results of CHRONO and MIROVA are most useful when read as null findings within well-defined populations, not as evidence of absence of benefit in untested subgroups.

The questions that the meeting left open will, in many cases, be addressed by ongoing randomized trials. Until those readouts are available, the available evidence supports continued use of approved agents within their labeled indications, with cautious extrapolation supported by clinical guidelines and molecular tumor board discussion where appropriate. The trajectory of the field is consistent with a transition from a period of agent scarcity to a period of agent abundance, in which the limiting factor is the quality of clinical decision-making rather than the number of available therapies.

0
0
Loading